Comparisons of Clinical Characteristics Between Tolvaptan and Carperitide Groups
| Tolvaptan (n = 54) | Carperitide (n = 55) | |
|---|---|---|
| Age (years) | 74 ± 12 | 75 ± 11 |
| Gender (male/female) | 29/25 | 33/22 |
| NYHA functional class (II/III and IV) | 11/43 | 11/44 |
| Body weight (kg) | 58.2 ± 13.1 | 56.3 ± 11.3 |
| Current or past smoker, n | 22 | 20 |
| Hypertension, n | 29 | 33 |
| Diabetes mellitus, n | 17 | 18 |
| Hyperlipidemia, n | 12 | 13 |
| Atrial fibrillation, n | 30 | 24 |
| Etiology of chronic heart failure, n | ||
| Dilated cardiomyopathy | 22 | 24 |
| Ischemic heart disease | 13 | 13 |
| Valvular heart disease | 6 | 5 |
| Hypertensive heart disease | 6 | 6 |
| Other | 7 | 7 |
| Heart rate (/min) | 91 ± 27 | 87 ± 26 |
| Systolic blood pressure (mmHg) | 130 ± 26 | 129 ± 27 |
| Diastolic blood pressure (mmHg) | 76 ± 16 | 74 ± 19 |
| Echocardiography | ||
| Left ventricular end diastolic diameter (mm) | 52 ± 12 | 53 ± 9 |
| Left ventricular ejection fraction (%) | 47 ± 18 | 44 ± 14 |
| Inferior vena cava (mm) | 20 ± 6 | 19 ± 6 |
| B-type natriuretic peptide* (pg/mL) | 544.3 (421.1) | 599.0 (397.1) |
| Blood urea nitrogen (mg/dL) | 24.5 ± 15.2 | 24.9 ± 12.7 |
| Serum creatinine (mg/dL) | 1.18 ± 0.76 | 1.24 ± 0.76 |
| Estimated GFR (mL/min/1.73m2) | 52.7 ± 22.5 | 50.0 ± 21.9 |
| Serum sodium (mEq/L) | 139 ± 6 | 140 ± 4 |
| Serum potassium (mEq/L) | 4.2 ± 0.6 | 4.1 ± 0.6 |
| Concomitant medication, n | ||
| Loop diuretics | 48 | 51 |
| Thiazide diuretics | 4 | 5 |
| Spironolactone | 30 | 33 |
| β-blocker | 29 | 35 |
| ACE inhibitors or ARBs | 23 | 31 |
| Mean administration duration (days) | 10 ± 8 | 8 ± 5 |
| Mean length of hospitalization (days) | 30 ± 22 | 29 ± 18 |
NYHA, New York Heart Association; GFR, glomerular filtration rate; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.
*
Skewed data are reported as median (inter-quartile range).